Rituxan for ALL

Last Modified: September 23, 2007

Share article


Dear OncoLink "Ask The Experts,"

My oncologist has started a treatment regimen of Rituxan for Acute Lymphocytic Leukemia, Ph+. I cannot find any research that indicates that Rituxan is used for treatment of this disease. I have only found where it is used for the treatment of lymphomas and to get patients ready for transplants. Can you clarify this?


Selina M. Luger, MD, Director of the Leukemia Program and Assistant Professor of Medicine at the University of Pennsylvania, responds:

Rituxan is a monoclonal antibody drug that is often used to treat lymphoid malignancies. The term "lymphoid" refers to anything involving lymphatic tissue, i.e. lymph nodes.

Acute Lymphocytic Leukemia , also known as ALL, is a type of lymphoid malignancy that travels through the blood. There have been reports of patients treated with Rituxan in combination with other therapeutic agents for ALL, both Ph-negative and Ph-positive types (Ph=Philadelphia chromosome). I am not aware of treatment with Rituxan as a single agent (given alone) for ALL. Treatment for Ph-positive disease should include one of the tyrosine kinase inhibitors (such as Gleevec/Imatinib or dasatinib).

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More